MCL1 and melanoma: Furthermore, downregulation of antiapoptotic Bcl-2 proteins (Bcl-2, Mcl-1, and Bcl-xL) was reported in melanoma cells upon treatment with different therapeutic strategies used for TRAIL sensitization, such as chemotherapeutics and inhibitors for metabolism, HDACs, and kinases.